Research process
ADVERSE REACTIONS, ADVERSE EVENT, TUMOURS, SOLID TUMORS, PATHOLOGY
The patients were treated with pembrolizumab 200 mg combined with cisplatin 75 mg/mPrior to drug treatment and again before surgery, the patients were examined with contrast-enhanced computed tomography of the head, neck and chest to assess the range of their lesions. The response to neoadjuvant therapy was evaluated using the RECIST 1.1 standard. The safety of the neoadjuvant therapy was determined by recording any adverse reactions within 30 d of receiving treatment. These were graded using the Common Terminology Criteria for Adverse Events (CTCAE 5.0). Surgery was defined as delayed if it was not performed within 7 weeks of the last neoadjuvant therapy. Postoperative pathology was evaluated based on the residual tumours in the resected specimens. Based on other solid tumors and KeyNote-689 research design (